SynthesisThe Journal of infectious diseases2013
Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax.
Synthesis in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 61 citations in OpenAlex.
- Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.Lancet (London, England) · 2023Trial
- Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.PLoS neglected tropical diseases · 2017Trial
- Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial.The Lancet. Infectious diseases · 2016Trial
- Trial
- Sub-RDT Plasmodium vivax infections and G6PD deficiency in Kayin State, Myanmar.Malaria journal · 2026Article
- Efficacy of primaquine-chloroquine combination onParasite epidemiology and control · 2026Article
- Community reservoirs of malaria parasites and gametocytes in Arba Minch district, southern Rift Valley, Ethiopia: a cross-sectional study.Malaria journal · 2026Article
- Risk factor for gametocyte carriage and gametocytemia in Plasmodium vivax and Plasmodium falciparum.Infectious diseases of poverty · 2025Article
- [Pilot Project for Early Diagnosis of Malaria Infection Using a Hematology Analyzer].Jugan geon-gang gwa jilbyeong · 2025Article
- [Effect of low-dose primaquine treatment on Plasmodium vivax recurrence and transmission-blocking activity in southwest Ethiopia: a longitudinal cohort study.Malaria journal · 2025Article
- Seasonal Dynamics of Symptomatic and Asymptomatic Plasmodium falciparum and Plasmodium vivax Infections in Coendemic Low-Transmission Settings, South Ethiopia.The American journal of tropical medicine and hygiene · 2024Article
- Transmission-blocking activities of artesunate, chloroquine, and methylene blue onAntimicrobial agents and chemotherapy · 2024Article
- Delayed gametocyte clearance inAntimicrobial agents and chemotherapy · 2024Article
- Article
- Potential hidden Plasmodium vivax malaria reservoirs from low parasitemia Duffy-negative Ethiopians: Molecular evidence.PLoS neglected tropical diseases · 2023Article
- Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.PLoS neglected tropical diseases · 2023Article
- Humanized mice for investigating sustained Plasmodium vivax blood-stage infections and transmission.Nature communications · 2022Article
- Comparison of PvLAP5 and Pvs25 qRT-PCR assays for the detection of Plasmodium vivax gametocytes in field samples preserved at ambient temperature from remote malaria endemic regions of Panama.PLoS neglected tropical diseases · 2022Article
- Novel highly-multiplexed AmpliSeq targeted assay forFrontiers in cellular and infection microbiology · 2022Article
- Identification of the asymptomatic Plasmodium falciparum and Plasmodium vivax gametocyte reservoir under different transmission intensities.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 5 countries.
Funding
Abstract
backgroundDesigning interventions that will reduce transmission of vivax malaria requires knowledge of Plasmodium vivax gametocyte dynamics.
methodsWe analyzed data from a randomized controlled trial in northwestern Thailand and 2 trials in Papua, Indonesia, to identify and compare risk factors for vivax gametocytemia at enrollment and following treatment.
resultsA total of 492 patients with P. vivax infections from Thailand and 476 patients (162 with concurrent falciparum parasitemia) from Indonesia were evaluable. Also, 84.3% (415/492) and 66.6% (209/314) of patients with monoinfection were gametocytemic at enrollment, respectively. The ratio of gametocytemia to asexual parasitemia did not differ between acute and recurrent infections (P = .48 in Thailand, P = .08 in Indonesia). High asexual parasitemia was associated with an increased risk of gametocytemia during follow-up in both locations. In Thailand, the cumulative incidence of gametocytemia between day 7 and day 42 following dihydroartemisinin + piperaquine (DHA + PIP) was 6.92% vs 29.1% following chloroquine (P < .001). In Indonesia, the incidence of gametocytemia was 33.6% following artesunate + amodiaquine (AS + AQ), 7.42% following artemether + lumefantrine, and 6.80% following DHA + PIP (P < .001 for DHA + PIP vs AS + AQ).
conclusionsP. vivax gametocyte carriage mirrors asexual-stage infection. Prevention of relapses, particularly in those with high asexual parasitemia, is likely the most important strategy for interrupting P. vivax transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.